Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who participated in and completed either study CGAL or study CGAM.~* Investigator judges the participant as reliable to follow all study procedures, keep all study visits, and be compliant with study requirements.~Exclusion Criteria:~* Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device (with the exception of Study CGAL or Study CGAM).~* Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF) (with the exception of Study CGAL or Study CGAM).~* A history of migraine variants that could implicate or could be confused with ischemia.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins.~* A history or presence of other medical illness that indicates a medical problem that would preclude study participation.~* Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator.~* Women who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Galcanezumab (Type: EXPERIMENTAL): Participants received 300 milligram (mg) Galcanezumab administered subcutaneously (SC) up to once a month.

Based on this trial design, predict the completion outcome and termination type (if applicable).